

Hans Ehrencrona

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5071621/hans-ehrencrona-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86
papers

5,674
citations

37
h-index

75
g-index

90
ext. papers

6,735
ext. citations

8.6
avg, IF

3.99
L-index

#	Paper	IF	Citations
86	PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. <i>Cell</i> , 1996 , 85, 863-73	56.2	704
85	PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. <i>Nature Cell Biology</i> , 2000 , 2, 302-9	23.4	493
84	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1347-61	27.4	286
83	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology</i> , 2018 , 19, 747-757	21.7	281
82	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010 , 42, 885-92	36.3	276
81	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. <i>Leukemia</i> , 2015 , 29, 999-1003	10.7	229
80	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1767-1778	36.3	186
79	A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. <i>Nature Genetics</i> , 2004 , 36, 1111-6	36.3	174
78	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009 , 113, 4497-504	30.4	158
77	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	153
76	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. <i>Cancer Research</i> , 2010 , 70, 9742-54	10.1	147
75	Combination of pegylated IFN- α 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. <i>Blood</i> , 2011 , 118, 3228-35	2.2	145
74	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018 , 39, 593-620	4.7	138
73	Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. <i>Leukemia</i> , 2017 , 31, 1108-1116	10.7	134
72	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020 , 38, 674-685	2.2	133
71	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. <i>Blood</i> , 2010 , 116, e1111-7	2.2	120
70	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. <i>Nature Medicine</i> , 2019 , 25, 1526-1533	50.5	102

69	PDGFB regulates the development of the labyrinthine layer of the mouse fetal placenta. <i>Developmental Biology</i> , 1999 , 212, 124-36	3.1	99
68	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016 , 48, 374-86	36.3	93
67	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009 , 18, 4442-56	5.6	91
66	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. <i>PLoS Biology</i> , 2011 , 9, e1001199	9.7	73
65	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015 , 24, 5345-55	5.6	68
64	Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 5905-13	2.2	68
63	Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. <i>Leukemia</i> , 2011 , 25, 1904-8	10.7	65
62	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016 , 7, 11375	17.4	64
61	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011 , 13, R110	8.3	62
60	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 3304-21	5.6	62
59	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
58	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019 , 40, 1557-1578	4.7	52
57	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1242-1250	9.7	51
56	Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. <i>Leukemia</i> , 2013 , 27, 1520-6	10.7	49
55	Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). <i>European Journal of Haematology</i> , 2015 , 94, 243-50	3.8	47
54	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014 , 16, 3416	8.3	46
53	Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. <i>Genetics in Medicine</i> , 2018 , 20, 452-457	8.1	44
52	Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. <i>Annals of Surgery</i> , 2011 , 253, 1147-54	7.8	44

51	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 645-57	4	44
50	RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib. <i>Leukemia</i> , 2014 , 28, 977-9	10.7	39
49	The c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. <i>Journal of Medical Genetics</i> , 2018 , 55, 15-20	5.8	36
48	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , 2014 , 10, e1004256	6	33
47	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2859-68	4	32
46	Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial. <i>Blood</i> , 2016 , 128, 787-787	2.2	32
45	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Human Mutation</i> , 2012 , 33, 690-702	4.7	31
44	Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome. <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 795-805	5	31
43	Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. <i>Epigenetics</i> , 2012 , 7, 1435-42	5.7	29
42	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. <i>British Journal of Cancer</i> , 2012 , 106, 2016-24	8.7	25
41	High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 113-21	5	24
40	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020 , 80, 624-638	10.1	22
39	The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial. <i>Leukemia</i> , 2011 , 25, 622-8	10.7	21
38	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 4732-47	5.6	21
37	Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study. <i>Blood</i> , 2014 , 124, 151-151	2.2	21
36	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 308-16	4	20
35	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. <i>Nature Communications</i> , 2020 , 11, 3747	17.4	18
34	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015 , 17, 61	8.3	16

33	Exploring the link between MORF4L1 and risk of breast cancer. <i>Breast Cancer Research</i> , 2011 , 13, R40	8.3	16
32	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
31	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012 , 14, R63	8.3	15
30	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. <i>Human Genetics</i> , 2011 , 130, 685-99	6.3	15
29	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). <i>British Journal of Cancer</i> , 2009 , 101, 2048-54	8.7	13
28	Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1032-8	4	13
27	Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012 , 87, 361-7	7.1	11
26	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. <i>PLoS ONE</i> , 2012 , 7, e35706	3.7	10
25	Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells. <i>Blood</i> , 2014 , 124, 812-812	2.2	9
24	No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial. <i>Blood</i> , 2016 , 128, 789-789	2.2	9
23	Analysis of mice lacking the heparin-binding splice isoform of platelet-derived growth factor A. <i>Molecular and Cellular Biology</i> , 2013 , 33, 4030-40	4.8	8
22	The Spectrum of Protein Truncating Variants in European Breast Cancer Cases. <i>Cancers</i> , 2020 , 12,	6.6	7
21	Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries. <i>Familial Cancer</i> , 2018 , 17, 31-41	3	6
20	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. <i>British Journal of Cancer</i> , 2011 , 104, 1356-61	8.7	6
19	How to handle genetic information: a comparison of attitudes among patients and the general population. <i>Public Health Genomics</i> , 2010 , 13, 396-405	1.9	6
18	Response: high ERG gene expression is an unfavorable prognostic marker in pediatric acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 1087-1088	2.2	5
17	Clinicians' Use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. <i>Journal of Community Genetics</i> , 2019 , 10, 61-71	2.5	5
16	U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner. <i>European Journal of Haematology</i> , 2008 , 81, 218-25	3.8	4

15	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 295-302	4.4	3
14	Stability of Conversion Factors for BCR-ABL Monitoring -Implications for the Frequency of Validation Rounds. <i>Blood</i> , 2010 , 116, 893-893	2.2	3
13	Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. <i>Blood</i> , 2015 , 126, 343-343	2.2	3
12	Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden. <i>Public Health Genomics</i> , 2020 , 23, 100-109	1.9	1
11	Functional implications of the p.Cys680Arg mutation in the MLH1 mismatch repair protein. <i>Molecular Genetics & Genomic Medicine</i> , 2014 , 2, 352-5	2.3	1
10	Whole-genome-amplified DNA as a source for mutational analysis underestimates the frequency of mutations in pediatric acute myeloid leukemia. <i>Leukemia</i> , 2013 , 27, 510-2	10.7	1
9	A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.. <i>Blood</i> , 2009 , 114, 3280-3280	2.2	1
8	Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006). <i>Blood</i> , 2013 , 122, 4032-4032	2.2	1
7	Hereditary colorectal cancer diagnostics in southern Sweden: retrospective evaluation and future considerations with emphasis on Lynch syndrome. <i>Journal of Community Genetics</i> , 2019 , 10, 259-266	2.5	1
6	FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study. <i>Blood</i> , 2021 , 138, 633-633	2.2	0
5	Public support for healthcare-mediated disclosure of hereditary cancer risk information: Results from a population-based survey in Sweden. <i>Hereditary Cancer in Clinical Practice</i> , 2020 , 18, 18	2.3	0
4	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. <i>Scientific Reports</i> , 2021 , 11, 14763	4.9	0
3	Potential of Digital PCR in CML Calibration. <i>Blood</i> , 2014 , 124, 1817-1817	2.2	
2	Genome-Wide Array-Based Methylation Profiling Reveals Preferential Methylation of Homeobox Transcription Factor Genes In Mantle Cell Lymphoma and Pro-Apoptotic Genes In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 536-536	2.2	
1	Genetic testing in women with early-onset breast cancer: a Traceback pilot study. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 307-315	4.4	